Clinical trials
T-cell Malignancies clinical trials
Below are recruiting t-cell malignancies clinical trials, each written for real people, not researchers. We’re tracking 266 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06854159RecruitingPhase 2
Odronextamab for diffuse large B-cell lymphoma before and after CAR T therapy
This trial tests a drug called odronextamab for people with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments. It aims to see if the drug can help before and after a type of immunotherapy called CAR T-cell therapy.
Sacramento, CaliforniaAges 18 years+ - NCT06043713RecruitingPhase 1
T-cell therapy for KRAS G12V solid tumors
This trial tests a personalized T-cell therapy designed to recognize and attack cancer cells with a specific KRAS G12V mutation. It is for people with metastatic solid tumors that have this mutation and a specific immune type (HLA-A*11:01).
Seattle, WashingtonAges 18 years+ - NCT07058103RecruitingPhase 2
Combination therapy for relapsed or refractory angioimmunoblastic T-cell lymphoma
This trial tests a combination of five drugs (tislelizumab, cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone) for patients with angioimmunoblastic T-cell lymphoma (AITL) that has come back or not responded to previous treatment. The goal is to see if this combination can shrink tumors or stop the disease from growing.
Xuzhou, JiangsuAges 18 years+ - NCT06909877RecruitingPhase 1/Phase 2
Study of HH2853 for relapsed or refractory peripheral T-cell lymphoma
This trial tests an experimental drug, HH2853, for people with certain types of T-cell lymphoma that have come back or not responded to prior treatments. It aims to see if the drug is safe and effective.
Chengdu, ChengduAges 18–75 - NCT05182957RecruitingPhase 2
Study of anti-PD-1, lenalidomide, and azacitidine for PTCL
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
Suzhou, JiangsuAges 18 years+ - NCT07378969Recruiting
Study on T-cell cancers after tisagenlecleucel treatment
This study looks at people who developed a new T-cell cancer after receiving the CAR-T therapy tisagenlecleucel (Kymriah). Researchers want to understand these rare cancers by testing stored tumor samples. You may be eligible if you had tisagenlecleucel and were later diagnosed with a T-cell malignancy.
Kurume, FukuokaAges 15–15 - NCT06909474RecruitingPhase 1
CD5-targeted CAR-NK therapy for relapsed T-cell blood cancers
This trial tests a new therapy using your own immune cells (NK cells) engineered to find and kill cancer cells that carry the CD5 protein. It is for people with T-cell acute lymphoblastic leukemia or certain T-cell lymphomas that have not responded to treatment or have returned.
Wuhan, HubeiAges 18–75 - NCT04752826RecruitingPhase 1/Phase 2
A new drug combo for advanced cancers
This trial tests a new experimental drug, BI-1808, alone or with an approved cancer drug called pembrolizumab (Keytruda). It's for people with advanced cancers that have stopped responding to standard treatments.
Duarte, CaliforniaAges 18 years+ - NCT03412877RecruitingPhase 2
Personalized immune-cell therapy for advanced metastatic cancers
This trial tests a personalized cell therapy made from your own immune cells, changed to recognize “neoantigens” on cancer cells. It’s designed for people with metastatic (advanced spread) solid cancers or certain other cancers who have tried standard treatments but cancer is still growing.
Bethesda, MarylandAges 18–72 - NCT05418088RecruitingPhase 1
CAR T-cell therapy for hard-to-treat B-cell cancers
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
Columbus, OhioAges 2 years+ - NCT05592015RecruitingPhase 2
Ruxolitinib for T-cell large granular leukemia
This Phase 2 study tests ruxolitinib, a targeted medicine, to improve outcomes in T-cell large granular lymphocytic leukemia (T-LGLL). It is for people whose disease is causing symptoms or who have already tried other treatment, with specific blood, infection, and medication requirements.
Boston, MassachusettsAges 18 years+ - NCT06815029RecruitingPhase 1
Modified immune cells for recurrent brain cancer
This trial tests a new treatment using your own immune cells that are genetically modified to find and attack brain tumor cells. It is for people with a type of brain cancer that has come back after standard therapy.
Duarte, CaliforniaAges 18 years+ - NCT05990465RecruitingPhase 1
LV20.19 CAR T-cells plus pirtobrutinib for relapsed B-cell lymphoma
This trial combines a new type of CAR T-cell therapy (LV20.19) with a targeted pill called pirtobrutinib to treat B-cell lymphomas that have come back or stopped responding. The goal is to see if this combination works better than each alone.
Milwaukee, WisconsinAges 18–81 - NCT05976997RecruitingPhase 2
Test duvelisib plus chidamide for newly diagnosed PTCL
This trial studies whether the combination of duvelisib and chidamide can treat newly diagnosed peripheral T-cell lymphoma (PTCL). Because it is a single-arm study, everyone gets the treatment, and the team monitors response and safety.
Wuhan, HubeiAges 18–70 - NCT06544265RecruitingPhase 1
SynKIR-310 for advanced B-cell lymphoma
This trial tests a new treatment called SynKIR-310 for people with B-cell non-Hodgkin lymphoma whose cancer has come back or not responded to at least 2 prior treatments. It may be an option if you've already had CAR T-cell therapy or cannot have it.
Denver, ColoradoAges 18 years+ - NCT05432635RecruitingPhase 1
CAR T-cell and vaccine treatment after stem cell transplant
This Phase 1 study tests a customized immune-cell treatment (CAR T-cells) plus a vaccine given after stem cell transplant for certain aggressive B-cell non-Hodgkin lymphomas. It aims to help your immune system better recognize and attack the lymphoma and to see how safe the approach is.
Duarte, CaliforniaAges 18 years+ - NCT06716619RecruitingPhase 1
Immune cell therapy for advanced solid tumors
This trial tests a new immune cell treatment made from your own lymph nodes for advanced solid tumors that haven't responded to standard therapies or have no good treatment options. It aims to see if this personalized cell therapy is safe and can help shrink tumors.
Guangzhou, GaungdongAges 18–75 - NCT06925685Enrolling by invitation
Long-term follow-up after CAR T-cell therapy
This study monitors participants who received a certain type of CAR T-cell therapy for cancer. It helps researchers understand long-term effects and safety.
Buffalo, New YorkAges Any age - NCT07647744RecruitingPhase 1
CD70-Targeted Cell Therapy for Advanced Kidney Cancer
This study tests a new cell-based treatment designed to target kidney cancer cells that have a protein called CD70. The treatment involves collecting your immune cells, modifying them in the lab, and infusing them back to fight the cancer. It's for patients with advanced kidney cancer who have already tried at least one standard immunotherapy.
ShanghaiAges 18–70 - NCT05801913RecruitingPhase 1
Personalized immune cell therapy plus a CMV vaccine
This Phase 1 study tests genetically modified immune cells (made from your own blood) plus a vaccine aimed at controlling CMV-related lymphoma. It’s for adults with intermediate or high-grade B-cell non-Hodgkin lymphoma who can’t get (or don’t want) certain standard stem-cell transplant options.
Duarte, CaliforniaAges 18 years+ - NCT04128072RecruitingPhase 2
Mogamulizumab plus skin radiation for cutaneous T-cell lymphoma
This trial studies mogamulizumab (an antibody medicine) plus total skin electron beam therapy (whole-skin radiation) to treat cutaneous T-cell lymphoma. It may help by improving skin symptoms and controlling the lymphoma after prior treatments.
CopenhagenAges 18 years+ - NCT07730515RecruitingPhase 1/Phase 2
Study of XNW5004 plus chemo for untreated T-cell lymphoma
This trial tests a new drug called XNW5004 combined with standard chemotherapy for people who have just been diagnosed with peripheral T-cell lymphoma and haven't had treatment yet. The goal is to see if adding XNW5004 helps more than chemotherapy alone.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05800405RecruitingEarly Phase 1
Radiation before CAR T therapy for large B-cell lymphoma
This early-phase study tests whether giving targeted radiation first can improve outcomes when you later receive CAR T-cell therapy for large B-cell lymphoma that has come back or is not responding to treatment. It may help shrink or control lymphoma spots before CAR T is infused.
Duarte, CaliforniaAges 18 years+ - NCT05648019RecruitingPhase 2
CD19 CAR T-cell therapy for tough B-cell blood cancers
This Phase 2 study tests a one-time CAR T-cell treatment aimed at CD19, a target found on many B-cell leukemias and lymphomas. It’s for people whose disease has come back or hasn’t responded to prior treatments, or who can’t have a stem cell transplant.
SingaporeAges birth–70 years
Hear when a new T-cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t-cell malignancies?
- Yes. Clin2 currently lists 266 recruiting t-cell malignancies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t-cell malignancies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t-cell malignancies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.